Iovance Biotherapeutics Inc Share Price Nasdaq
Equities
US53619R1023
Biotechnology & Medical Research
Sales 2024 * | 161M 13.47B | Sales 2025 * | 413M 34.45B | Capitalization | 3.25B 271B |
---|---|---|---|---|---|
Net income 2024 * | -352M -29.36B | Net income 2025 * | -245M -20.43B | EV / Sales 2024 * | 19.3 x |
Net cash position 2024 * | 133M 11.12B | Net cash position 2025 * | 251M 20.9B | EV / Sales 2025 * | 7.27 x |
P/E ratio 2024 * |
-8.97
x | P/E ratio 2025 * |
-16.1
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.7% |
Latest transcript on Iovance Biotherapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Frederick Vogt
CEO | Chief Executive Officer | 50 | 30/16/30 |
Director of Finance/CFO | 51 | 14/20/14 | |
Brian Shew
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Merrill McPeak
BRD | Director/Board Member | 88 | 20/11/20 |
Director/Board Member | 56 | 07/16/07 | |
Michael Weiser
BRD | Director/Board Member | 61 | 15/18/15 |
1st Jan change | Capi. | |
---|---|---|
-19.74% | 10.82B | |
-32.31% | 2.11B | |
-14.15% | 2.08B | |
-25.30% | 1.48B | |
+20.08% | 1.02B | |
-2.62% | 733M | |
-31.33% | 391M | |
-43.27% | 383M | |
+29.03% | 332M |